

REGEN THERAPEUTICS LTD (NewCo)

Tim Shilton
28/1/2011

CURRENT ANALYSIS

- Increasing distribution/sales revenue and growth potential
- Reduced overheads
- All non-loan debt settled
- Production capability secured (filtration rig and patents)
- Short-term Finance to sustainability in place
- Non CLN IP potentially valuable
- Neurological/nutraceutical expertise and contacts
- Trading losses expected to be carried forward
- Benefits of private company but with trading facility
- Longer term – exit potential (trade sale, IPO)

OBJECTIVES

■ Short-term

- Secure new licensees/territories
- Assist existing licensees to optimise sales
- Increase revenue to RGT (eg RGT Tablets)
- Closely monitor CF forecast vs actual and manage business accordingly
- Regular shareholder updates

■ Long-term

- Add new profitable products where distribution contacts can be used
- Create value and exit opportunities for shareholders (eg trade sale, IPO)

COLOSTRININ™

Market Rollout

- Australasia - Metagenics, Inc. - October 2007
- N. America - Metagenics, Inc. - December 2007
- Cyprus - Golgi Ltd (first EU launch) - October 2008
- Poland - Tagerr - May 2009
- UK - PRG Nutraceuticals Ltd - October 2009
- Turkey - Eczacibasi - May 2010
- India - USV - July 2010
- South Korea – LGLS – December 2010
- Ongoing discussions: South America (Framingham - MTA), Middle East/North Africa, China

COMMUNICATIONS

- Website (contact e-mail address)
 - Regular trading updates
 - Key trading announcements
 - Clarification announcements (key shareholder questions)
 - Financial reports (6m interim/annual)
- Direct contact
 - Annual General Meeting
 - Ad Hoc Meetings/news release as appropriate

REGULATORY

Import/Marketing Claims

- USA: Self-affirmed approval by Metagenics under Dietary Supplement Health Education Act (DSHEA). Justified by colostrum already being part of human food chain
- Marketed in other countries where USA marketing can be leveraged and import/approval/promotion as 'food/nutraceutical' can be achieved using existing activity, safety and clinical data
- **Not** partnered in most EU countries due to need for clinical trial in target population (AAMI/MCI) under EU Claims directive
- **Not** partnered in Japan due to old law preventing import of 'colostrum products'

SUPPLY OPTIONS

- API: CLN Freeze-dried Powder (1% in maltodextrin)
 - 1Kg makes approximately 30 x 3,300 tablets each containing 10mg 1% CLN powder (ie 100 microgram CLN per tablet)
- Bulk tablets (ReGen – white/orange flavour)
 - Bulk pots/blisters
- Bulk 30 tablet blisters plus local brand name (ex-Metagenics)
- Finished USA 'Cognisure' packs (ex-Metagenics)
- To date all of the above options have been subject to an additional % royalty on net sales when the finished product is sold in the market **or** an upfront licensing fee

NB. Other supply options and price discounts for high volume can be discussed.

CLN could be added into existing foods eg yoghurt.

Original launch/current USA dosing regimen is 'one tablet on alternate days for three weeks followed by no dosing for two weeks'. This is the dose regimen used in clinical studies. This is in the process of being changed to 'one tablet daily'. This is already the dose regimen in UK, Cyprus and Australia.

REGEN TABLETS

Orange flavoured

Manufactured in
USA



FEATURES/BENEFITS

- Active from safe natural source
- Made to high quality standards
- Significant body of scientific/clinical evidence
- Small active daily dose, easily incorporated into various delivery forms
- Activity on multiple aspects of Alzheimer's disease/cognitive impairment as compared with single activity of competitors

Positioning:

Support for Healthy Brain Aging and Cognition

The 'cornerstone' of managing age-related cognition problems